KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Acquisitions (2018 - 2021)

Amneal Pharmaceuticals has reported Acquisitions over the past 3 years, most recently at $72.7 million for Q4 2021.

  • Quarterly results put Acquisitions at $72.7 million for Q4 2021, changed N/A from a year ago — trailing twelve months through Dec 2022 was $72.7 million (down 50.38% YoY), and the annual figure for FY2022 was $84.7 million, down 42.19%.
  • Acquisitions for Q4 2021 was $72.7 million at Amneal Pharmaceuticals, down from $73.8 million in the prior quarter.
  • Over the last five years, Acquisitions for AMRX hit a ceiling of $253.6 million in Q1 2020 and a floor of -$2.6 million in Q3 2020.
  • Median Acquisitions over the past 3 years was $38.0 million (2018), compared with a mean of $66.9 million.
  • Peak annual rise in Acquisitions hit 19587.47% in 2021, while the deepest fall reached 19587.47% in 2021.
  • Amneal Pharmaceuticals' Acquisitions stood at $3.3 million in 2018, then plummeted by 179.76% to -$2.6 million in 2020, then soared by 2854.36% to $72.7 million in 2021.
  • The last three reported values for Acquisitions were $72.7 million (Q4 2021), $73.8 million (Q2 2021), and -$2.6 million (Q3 2020) per Business Quant data.